肠道假性阻塞治疗市场－全球产业规模、份额、趋势、机会及预测（依病症、诊断、治疗、最终用户、地区及竞争格局划分，2021-2031年）

全球肠道假性阻塞治疗市场预计将从 2025 年的 210.8 亿美元成长到 2031 年的 285.9 亿美元，复合年增长率为 5.21%。

该市场包括旨在治疗非机械性肠阻塞性肠道推进功能障碍的药物疗法、营养支持系统和外科手术。其增长主要受糖尿病和阿片类药物引起的肠道功能障碍等继发性病因日益普遍以及用于恢復胃肠动力的刺激剂不断改进的推动。

然而，限制市场成长的主要障碍在于难以做出准确诊断，这往往导致治疗延迟和治疗错误。近期临床研究结果也表明，目前对支持性治疗的依赖程度较高，而非根治性治疗。根据欧洲肠道功能障碍復健和移植网络2024年的一项调查，87.7%的受访儿童患者需要长期营养支持，这凸显了该领域长期管理治疗的迫切需求。

市场驱动因素

伴随而来的慢性疾病和神经系统疾病的日益增多，显着扩大了全球肠道假性阻塞治疗市场的潜在患者群体。由于这种疾病通常是糖尿病和全身性硬化症等全身性疾病的继发性併发症，这些合併症日益加重的全球负担直接催生了对肠道动力管理解决方案的需求。例如，根据国际糖尿病联盟 (IDF) 2024 年的报告，全球约有 5.89 亿成年人将患有糖尿病，这使得该族群面临次发性胃肠神经病变的巨大风险。这种流行病学上的成长需要市场做出持续的反应，因为这些慢性疾病的进展往往会导致严重的肠道动力障碍，从而增加对药物治疗和长期营养支持的需求，以解决相关的胃肠功能障碍。

同时，针对罕见运动障碍的研发策略正推动新疗法的涌现。产业相关人员正加大对精准医疗和早期计划的投入，以解决肠道假性阻塞的复杂病理学，超越单纯的症状管理。这一趋势在近期的资金筹措活动中显而易见。根据FirstWord Pharma报道，ThirtyFiveBio于2024年7月接受643,371英镑的津贴，用于加速开发First-in-ClassGPR35抑制剂。更广泛的基础设施投资也为创新提供了进一步的支持。英国研究与创新署（UKRI）表示，将于2024年9月推出的「生物医学催化剂」竞赛将为致力于开发包括罕见疾病在内的健康问题解决方案的公司提供高达1500万英镑的资金，以检验这一服务不足领域中的新型生物标的。

市场挑战

准确诊断的困难是全球肠道假性阻塞治疗市场扩张的主要障碍。由于腹胀和腹痛等症状与机械性阻塞的症状极为相似，临床医师常误诊。这种诊断上的混淆常常导致患者接受不必要的探查性手术或不恰当的治疗，而非必要的药物或营养疗法。因此，目标患者群体长期未被识别或治疗不当，阻碍了某些市场疗法的广泛应用。

这种普遍存在的管理不善严重限制了非侵入性治疗的潜在商机。当医疗服务提供者无法区分假性肠阻塞和机械性肠阻塞时，就会延误促动力药和特殊营养补充剂的及时使用，从而降低这些产品的整体市场渗透率。这个问题十分严重；英国皇家外科医学院2024年的一项服务评估显示，仅有6.7%的急性结肠假性肠梗阻患者接受了最佳保守治疗，这表明在标准治疗通讯协定的适当应用方面存在严重不足。这种低效率不仅阻碍了市场成长，也分散了医疗资源，使其无法用于推动产业价值的长期管理策略。

市场趋势

新型高选择性5-HT4受体促效剂的研发正为肠假性阻塞的药物治疗领域注入新的活力，解决了传统促动力药物存在的安全隐患。这一趋势的核心在于开发工程化合物，例如那罗那必利，它利用双重作用机制刺激肠道蠕动，同时避免了非选择性药物相关的心血管风险。该领域的进展正在加速，从理论概念转向旨在验证其恢復胃肠推进功能疗效的特定后期临床试验。随着相关人员扩大这些临床实验疗法的应用范围，该领域已取得关键性进展。根据Renexxion Ireland Ltd.于2024年8月发布的新闻稿，扩展的IIb期临床试验「MOVE-IT」已在美国首次启动，评估那罗那必利的安全性和有效性。这标誌着在检验此类高选择性促效剂对更广泛的动力障碍的疗效方面迈出了关键一步。

同时，使用类升糖素肽-2 (GLP-2) 类似物改进的长期家庭肠外营养通讯协定，正将治疗从单纯的支持性护理转变为积极的肠道復健。此策略旨在提高残存肠道的吸收能力，并减少严重肠道功能障碍患者所需的肠外营养量和频率。透过使用促进肠道适应的药物，临床医生可以降低导管相关感染疾病等危及生命的风险。近期数据支持了这项治疗益处。根据Ironwood Pharmaceuticals于2024年10月发布的STARS III期试验最新结果，与安慰剂相比，阿普拉鲁肽治疗使每週肠外营养支持量显着减少了25.5%，证实了新一代类似物有望从根本上改变长期管理方法。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球肠道假性阻塞治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按病情（急性与慢性）
  • 透过诊断（身体检查、切片检查、血液检查、排放试验、影像检查、其他）
  • 依治疗方法（药物治疗、手术、饮食疗法、其他）
  • 按最终使用者（医院/诊所、门诊护理中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美肠道假性阻塞治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲肠道假性阻塞治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区肠道假性阻塞治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东及非洲肠道假性阻塞治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲肠道假性阻塞治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球肠道假性阻塞治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Pfizer Inc.
• Cipla Inc.
• GlaxoSmithKline Plc.
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• Novartis AG
• Johnson & Johnson
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche AG
• Lupin Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Intestinal Pseudo Obstruction Treatment Market is projected to expand from USD 21.08 Billion in 2025 to USD 28.59 Billion by 2031, registering a CAGR of 5.21%. This market encompasses pharmacological treatments, nutritional support systems, and surgical procedures designed to manage impaired intestinal propulsion characterized by the absence of mechanical blockage. Growth is primarily fuelled by the rising detection of secondary etiologies, including diabetes and opioid-induced bowel dysfunction, alongside continuous improvements in prokinetic medications intended to reinstate gastrointestinal motility.

Conversely, a major hurdle restricting market growth is the difficulty of establishing an accurate diagnosis, which often leads to postponed treatment and therapeutic errors. The heavy dependence on supportive measures rather than curative solutions is highlighted by recent clinical findings. According to a 2024 survey by the Network for Intestinal Failure Rehabilitation and Transplantation in Europe, 87.7% of evaluated pediatric patients necessitated permanent nutritional support, emphasizing the urgent and continuing need for long-term management therapies in this field.

Market Driver

The expanding prevalence of associated chronic and neurological diseases is substantially increasing the potential patient base for the Global Intestinal Pseudo Obstruction Treatment Market. Since this condition often arises as a secondary issue stemming from systemic illnesses like diabetes mellitus and systemic sclerosis, the growing global burden of these comorbidities creates a direct demand for motility management solutions. For example, the International Diabetes Federation reported in 2024 that roughly 589 million adults globally were living with diabetes, a population highly susceptible to secondary gastrointestinal neuropathies. This epidemiological increase demands a consistent market response, as the advancement of such chronic diseases frequently triggers severe intestinal dysmotility, fueling the need for pharmacological interventions and long-term nutritional support to handle the ensuing gastrointestinal failure.

Concurrently, a strategic emphasis on Research and Development for rare motility disorders is driving the creation of new therapeutic options. Industry stakeholders are increasingly investing in precision medicine and early-stage projects to tackle the intricate pathophysiology of intestinal pseudo-obstruction, aiming to go beyond basic symptom control. This trend is illustrated by recent funding activities; according to FirstWord Pharma, ThirtyFiveBio received a £643,371 grant in July 2024 to speed up the development of first-in-class GPR35 inhibitors for gastrointestinal conditions. This push for innovation is further backed by wider infrastructure investments; as per UK Research and Innovation, a biomedical catalyst competition introduced in September 2024 offered a share of up to £15 million to companies creating solutions for health issues, including rare diseases, validating new biologic targets for this underserved sector.

Market Challenge

The difficulty of securing an accurate diagnosis represents a significant obstacle to the expansion of the Global Intestinal Pseudo Obstruction Treatment Market. Because symptoms like abdominal distension and pain closely resemble those of mechanical obstruction, clinicians often misjudge the underlying condition. This diagnostic confusion frequently leads to patients enduring needless exploratory surgeries or receiving unsuitable treatments instead of the necessary pharmacological or nutritional therapies. As a result, the uptake of specific market treatments is hindered because the target patient group remains unidentified or is managed incorrectly for extended durations.

This pervasive mismanagement substantially restricts potential revenue opportunities for non-invasive therapeutic agents. When medical providers fail to differentiate pseudo-obstruction from mechanical blockages, the prompt use of prokinetics or specialized nutritional formulas is postponed, lowering the overall market penetration of these products. The scale of this problem is significant; a 2024 service evaluation by the Royal College of Surgeons of England found that only 6.7% of patients with acute colonic pseudo-obstruction received optimal conservative management, indicating a serious gap in the proper application of standard care protocols. Such inefficiencies not only impede market growth but also redirect healthcare resources away from the long-term management strategies that generate industry value.

Market Trends

The landscape for pharmacological treatment of intestinal pseudo-obstruction is being invigorated by the development of novel high-selectivity 5-HT4 receptor agonists, which address the safety concerns associated with earlier prokinetic drugs. This trend centers on engineering compounds such as naronapride that utilize dual-action mechanisms to stimulate enteric motility without imposing the cardiovascular risks linked to non-selective agents. Progress in this field is quickening, moving from theoretical concepts to concrete late-stage trials aimed at proving efficacy in restoring gastrointestinal propulsion. A significant milestone was reached when stakeholders broadened the scope of these investigative treatments; according to a press release from Renexxion Ireland Ltd. in August 2024 regarding the expansion of the Phase 2b MOVE-IT study, the first patient in the United States was dosed to assess the safety and efficacy of naronapride, representing a crucial move toward validating this class of highly selective agonists for wider motility disorders.

Simultaneously, the refinement of long-term home parenteral nutrition protocols is transforming treatment from merely supportive care to active intestinal rehabilitation through the use of glucagon-like peptide-2 (GLP-2) analogs. This strategy seeks to improve the absorptive capabilities of the remaining bowel, thereby decreasing the volume and frequency of parenteral support needed by patients suffering from severe intestinal failure. By utilizing agents that encourage intestinal adaptation, clinicians can mitigate life-threatening risks such as catheter-related infections. Recent data supports this therapeutic efficacy; according to an October 2024 update from Ironwood Pharmaceuticals on the Phase 3 STARS trial, apraglutide treatment led to a statistically significant 25.5% reduction in weekly parenteral support volume compared to a placebo, affirming the potential of next-generation analogs to fundamentally reshape long-term management approaches.

Key Market Players

• Pfizer Inc.
• Cipla Inc.
• GlaxoSmithKline Plc.
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• Novartis AG
• Johnson & Johnson
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche AG
• Lupin Limited

Report Scope

In this report, the Global Intestinal Pseudo Obstruction Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Intestinal Pseudo Obstruction Treatment Market, By Condition

• Acute v/s Chronic

Intestinal Pseudo Obstruction Treatment Market, By Diagnosis

• Physical Examination
• Biopsy
• Blood Test
• Gastric Emptying Tests
• Imaging Tests
• Others

Intestinal Pseudo Obstruction Treatment Market, By Treatment

• Medication
• Surgery
• Diet
• Others

Intestinal Pseudo Obstruction Treatment Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Intestinal Pseudo Obstruction Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Intestinal Pseudo Obstruction Treatment Market.

Available Customizations:

Global Intestinal Pseudo Obstruction Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Intestinal Pseudo Obstruction Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Condition (Acute v/s Chronic)
  • 5.2.2. By Diagnosis (Physical Examination, Biopsy, Blood Test, Gastric Emptying Tests, Imaging Tests, Others)
  • 5.2.3. By Treatment (Medication, Surgery, Diet, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Intestinal Pseudo Obstruction Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Condition
  • 6.2.2. By Diagnosis
  • 6.2.3. By Treatment
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Intestinal Pseudo Obstruction Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Condition
      • 6.3.1.2.2. By Diagnosis
      • 6.3.1.2.3. By Treatment
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Intestinal Pseudo Obstruction Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Condition
      • 6.3.2.2.2. By Diagnosis
      • 6.3.2.2.3. By Treatment
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Intestinal Pseudo Obstruction Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Condition
      • 6.3.3.2.2. By Diagnosis
      • 6.3.3.2.3. By Treatment
      • 6.3.3.2.4. By End User

7. Europe Intestinal Pseudo Obstruction Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Condition
  • 7.2.2. By Diagnosis
  • 7.2.3. By Treatment
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Intestinal Pseudo Obstruction Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Condition
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By Treatment
      • 7.3.1.2.4. By End User
  • 7.3.2. France Intestinal Pseudo Obstruction Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Condition
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By Treatment
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Intestinal Pseudo Obstruction Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Condition
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By Treatment
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Intestinal Pseudo Obstruction Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Condition
      • 7.3.4.2.2. By Diagnosis
      • 7.3.4.2.3. By Treatment
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Intestinal Pseudo Obstruction Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Condition
      • 7.3.5.2.2. By Diagnosis
      • 7.3.5.2.3. By Treatment
      • 7.3.5.2.4. By End User

8. Asia Pacific Intestinal Pseudo Obstruction Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Condition
  • 8.2.2. By Diagnosis
  • 8.2.3. By Treatment
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Intestinal Pseudo Obstruction Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Condition
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By Treatment
      • 8.3.1.2.4. By End User
  • 8.3.2. India Intestinal Pseudo Obstruction Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Condition
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By Treatment
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Intestinal Pseudo Obstruction Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Condition
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By Treatment
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Intestinal Pseudo Obstruction Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Condition
      • 8.3.4.2.2. By Diagnosis
      • 8.3.4.2.3. By Treatment
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Intestinal Pseudo Obstruction Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Condition
      • 8.3.5.2.2. By Diagnosis
      • 8.3.5.2.3. By Treatment
      • 8.3.5.2.4. By End User

9. Middle East & Africa Intestinal Pseudo Obstruction Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Condition
  • 9.2.2. By Diagnosis
  • 9.2.3. By Treatment
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Intestinal Pseudo Obstruction Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Condition
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By Treatment
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Intestinal Pseudo Obstruction Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Condition
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By Treatment
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Intestinal Pseudo Obstruction Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Condition
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By Treatment
      • 9.3.3.2.4. By End User

10. South America Intestinal Pseudo Obstruction Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Condition
  • 10.2.2. By Diagnosis
  • 10.2.3. By Treatment
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Intestinal Pseudo Obstruction Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Condition
      • 10.3.1.2.2. By Diagnosis
      • 10.3.1.2.3. By Treatment
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Intestinal Pseudo Obstruction Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Condition
      • 10.3.2.2.2. By Diagnosis
      • 10.3.2.2.3. By Treatment
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Intestinal Pseudo Obstruction Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Condition
      • 10.3.3.2.2. By Diagnosis
      • 10.3.3.2.3. By Treatment
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Intestinal Pseudo Obstruction Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Cipla Inc.
• 15.3. GlaxoSmithKline Plc.
• 15.4. Teva Pharmaceutical Industries Ltd.
• 15.5. Eli Lilly and Company
• 15.6. Novartis AG
• 15.7. Johnson & Johnson
• 15.8. Dr. Reddy's Laboratories Ltd.
• 15.9. F. Hoffmann-La Roche AG
• 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer